Company news

Vistagen Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting

June 1, 2022

VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder

May 4, 2022

VistaGen Appoints Reid Adler as Chief Legal Officer

May 1, 2022

VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B

April 11, 2022

VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

February 9, 2022

VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update

November 9, 2021

VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021

November 3, 2021

VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder

October 13, 2021

VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B’s Potential Anti-Anxiety Activity via Peripheral Nasal Neurons without Entry into the Brain

October 4, 2021

VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2

September 12, 2021

VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update

August 11, 2021

VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors

July 21, 2021

VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors

July 6, 2021

VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update

June 28, 2021

VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021

June 24, 2021

VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder

May 25, 2021

VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer

May 3, 2021

VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors

April 26, 2021

VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021

February 10, 2021

VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

January 5, 2021

VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders

December 29, 2020

VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering

December 21, 2020

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering

December 17, 2020

VistaGen Therapeutics Announces Proposed Underwritten Public Offering

December 16, 2020

VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression

December 9, 2020

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress

November 11, 2020

VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid

September 2, 2020

VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress

August 12, 2020

VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering

August 9, 2020

VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering

August 4, 2020

VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration

August 3, 2020

VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock

August 1, 2020

VistaGen Therapeutics Announces Proposed Public Offering of Common Stock

July 30, 2020

VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder

July 22, 2020

VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update

June 28, 2020

VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

June 24, 2020

VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions

May 26, 2020

VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)

May 17, 2020

VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

April 27, 2020

VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million

March 24, 2020

VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder

February 19, 2020

VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview

February 12, 2020

VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects

February 10, 2020

VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

January 29, 2020

VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans

December 18, 2019

U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder

December 9, 2019

VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder

November 13, 2019

VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview

November 6, 2019

VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease

October 27, 2019

VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder

October 7, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.